Who Exports Mesalamine from India — 103 Suppliers Behind a $1.3B Market
India's mesalamine export market is supplied by 103 active exporters who collectively shipped $1.3B across 3,779 shipments. ZYDUS LIFESCIENCES LIMITED leads with a 78.8% market share, followed by SUN PHARMACEUTICAL INDUSTRIES LIMITED and CADILA HEALTHCARE LIMITED. The top 5 suppliers together control 98.5% of total export value, reflecting a concentrated market structure.
Top Mesalamine Exporters from India — Ranked by Export Value
ZYDUS LIFESCIENCES LIMITED is the leading mesalamine exporter from India, holding a 78.8% share of the $1.3B market across 3,779 shipments from 103 exporters. The top 5 suppliers — ZYDUS LIFESCIENCES LIMITED, SUN PHARMACEUTICAL INDUSTRIES LIMITED, CADILA HEALTHCARE LIMITED, ANNORA PHARMA PRIVATE LIMITED, CADILA HEALTHCARE LTD — collectively control 98.5% of total export value, indicating a highly concentrated market. Individual shares are: ZYDUS LIFESCIENCES LIMITED (78.8%), SUN PHARMACEUTICAL INDUSTRIES LIMITED (13.7%), CADILA HEALTHCARE LIMITED (3.5%), ANNORA PHARMA PRIVATE LIMITED (1.8%), CADILA HEALTHCARE LTD (0.7%).
Top Mesalamine Exporters from India
Ranked by export value · 103 active suppliers · Indian Customs (DGFT) data
| # | Supplier & Formulations | Value | Ctry. | Share |
|---|---|---|---|---|
| 1 | ZYDUS LIFESCIENCES LIMITED MESALAMINE DELAYED RELEASE TABLETS 1.2 GMJARD 1 MESALAMINE DR T 1 2GM 4X8S SL MXMESALAMINE DR TABLETS 1.2 GM 2X8S SL MX | $1.0B | 6 | 78.8% |
| 2 | SUN PHARMACEUTICAL INDUSTRIES LIMITED MESALAMINE DELAYED RELEASE TABLETS 1.2 GMMESALAMINE DELAYED RELEASE TABLETS USP 1MESACOL TAB 400MG (MESALAMINE TABLETS 40 | $180.4M | 11 | 13.7% |
| 3 | CADILA HEALTHCARE LIMITED MESALAMINE DELAYED RELEASE TABLETS 1.2 GM | $46.4M | 1 | 3.5% |
| 4 | ANNORA PHARMA PRIVATE LIMITED MESALAMINE DELAYED RELEASE TABLETS 1.2 GM | $24.1M | 1 | 1.8% |
| 5 | CADILA HEALTHCARE LTD MESALAMINE DELAYED RELEASE TABLETS 1.2 GM | $9.7M | 1 | 0.7% |
| 6 | SUN PHARMACEUTICAL INDUSTRIES LTD MESALAMINE DELAYED RELEASE TABLETS 1.2 GMMESALAMINE DELAYED RELEASE TABLETS USP 1MESACOL TAB 400MG (MESALAMINE TABLETS 40 | $4.3M | 2 | 0.3% |
| 7 | ATHENA DRUG DELIVERY SOLUTIONS PRIVATE LIMITED MESALAMINE PELLETSMESALAMINE PELLETS,MFG.DT:NOV 2022,EXP.DMESALAMINE PELLETS :- MESALAMINE 6 000 K | $4.2M | 1 | 0.3% |
| 8 | ALKEM LABORATORIES LIMITED MESALAMINE DELAYED RELEASE TABLETS 1.2 GM | $4.0M | 1 | 0.3% |
| 9 | ENCUBE ETHICALS PRIVATE LIMITED MESALAMINE DELAYED RELEASE TABLETS 1.2 GM | $2.6M | 1 | 0.2% |
| 10 | MYLAN LABORATORIES LIMITED MESALAMINE DELAYED RELEASE TABLETS 1.2 GM | $1.3M | 2 | 0.1% |
| 11 | ALEMBIC PHARMACEUTICALS LIMITED MESALAMINE DELAYED RELEASE TABLETS 1.2 GM | $1.1M | 1 | 0.1% |
| 12 | LAWRENCE WALTER | $297.2K | 3 | 0.0% |
| 13 | PLEASANT EXPORTS MESACOL OD 1200 MG 150 TAB MESALAMINE PROLONGEDMESACOL OD TABMESACOL 800 TAB | $265.6K | 2 | 0.0% |
Related Analysis
Supplier Certification & Compliance Matrix
FDA, WHO-GMP, and EU GMP status for top Mesalamine exporters
| Supplier | US FDA | WHO-GMP | EU GMP | ANDAs | Notes |
|---|---|---|---|---|---|
| Zydus Lifesciences Limited | Approved | Yes | Yes | 322 (as of June 30, 2022) | Received FDA warning letter in August 2024; compliance issues addressed by Decem |
| Sun Pharmaceutical Industries Limited | Approved | Yes | Yes | 80+ | Offers over 80 FDA-approved generic products across various therapeutic categori |
| Alembic Pharmaceuticals Limited | Approved | Yes | Yes | Multiple approvals between 2024 and 2025 | Received multiple FDA approvals for generic medicines between 2024 and 2025. |
| Cadila Pharmaceuticals Limited | Approved | Yes | Yes | Not specified | Received FDA warning in 2014 for manufacturing practice discrepancies; current s |
TransData Nexus reviewed the regulatory standing of 4 leading Mesalamine exporters from India. 4 hold US FDA facility approvals, 4 maintain WHO-GMP certification, and 4 are EU GMP compliant. For regulated markets (US, EU, Australia), prioritise suppliers with active FDA or EU GMP approvals. For semi-regulated markets (Africa, ASEAN, Latin America), WHO-GMP certification is the minimum recommended standard.
Certification status compiled from publicly available regulatory databases including FDA Orange Book, WHO Prequalification database, and EMA GMP registry. Buyers should independently verify compliance status with the relevant regulatory authority before placing orders.
TransData Nexus Research · Mar 2026
Manufacturing Hub Analysis — Vendor Proximity
India's pharmaceutical clusters relevant to Mesalamine sourcing
1Hyderabad — Bulk Drug Capital
Hyderabad, often referred to as the "Bulk Drug Capital of India," is a major hub for Active Pharmaceutical Ingredients (APIs) production. The city hosts numerous manufacturing facilities specializing in APIs, including Mesalamine. Companies like Metrochem API Private Limited, established in 2004, operate in this region, offering Mesalamine APIs and adhering to international quality standards.
2Ahmedabad-Vadodara — Formulations Hub
The Ahmedabad-Vadodara corridor in Gujarat is renowned for its pharmaceutical formulations industry. This region is home to leading companies such as Zydus Lifesciences Limited and Sun Pharmaceutical Industries Limited, which are significant contributors to Mesalamine exports. Zydus Lifesciences Limited alone accounted for $1,038.9 million in Mesalamine exports, representing 78.8% of the total exports in this category.
3Mumbai-Thane-Raigad — Export Gateway
The Mumbai-Thane-Raigad belt in Maharashtra serves as a critical export gateway for pharmaceutical products. With its proximity to major ports and well-established infrastructure, this region facilitates the efficient export of Mesalamine formulations to international markets. Companies operating here benefit from streamlined logistics and access to global shipping routes.
4Baddi-Nalagarh — Tax Incentive Zone
The Baddi-Nalagarh region in Himachal Pradesh has emerged as a prominent pharmaceutical manufacturing zone, largely due to favorable tax incentives. This area hosts numerous pharmaceutical units that contribute to the production and export of various drugs, including Mesalamine. The tax benefits and supportive policies have attracted significant investment, bolstering the region's pharmaceutical output.
5Sourcing Recommendations
- Diversify Supplier Base: While Zydus Lifesciences Limited is the dominant exporter of Mesalamine, accounting for 78.8% of exports, it's prudent to engage with multiple suppliers to mitigate risks associated with over-reliance on a single source.
- Evaluate Supplier Capabilities: Assess the manufacturing capabilities and quality standards of potential suppliers, particularly those in Hyderabad and Ahmedabad-Vadodara, to ensure they meet international regulatory requirements.
- Leverage Export Infrastructure: Utilize the logistical advantages offered by the Mumbai-Thane-Raigad region to streamline the export process and reduce lead times.
- Monitor Regulatory Compliance: Stay informed about regulatory changes and compliance requirements in key export destinations, especially the United States, which accounts for 98.6% of Mesalamine exports.
By strategically engaging with suppliers across these pharmaceutical clusters and leveraging regional strengths, companies can optimize their Mesalamine sourcing and export operations.
Recent M&A, Collaborations & Capacity Expansions
Industry developments among top Mesalamine exporters from India
Zydus Lifesciences Limited — Bayer acquires full ownership of Bayer Zydus Pharma
Bayer acquired the remaining 25% stake in Bayer Zydus Pharma Private Limited from Zydus Lifesciences, securing complete control of the joint venture. - IMPACT: This divestment allows Zydus to reallocate resources, potentially enhancing its focus on Mesalamine production and export.
Impact: This divestment allows Zydus to reallocate resources, potentially enhancing its focus on Mesalamine production and export.
Zydus Lifesciences Limited — Zydus acquires Agenus' CDMO business
Zydus acquired the contract development and manufacturing organization (CDMO) business of Agenus, including two biologics manufacturing sites in Emeryville and Berkeley. - IMPACT: This acquisition may bolster Zydus' manufacturing capabilities, potentially impacting Mesalamine production and export capacity.
Impact: This acquisition may bolster Zydus' manufacturing capabilities, potentially impacting Mesalamine production and export capacity.
Zydus Lifesciences Limited — Zydus sells animal health business to consortium
Zydus sold its India-focused animal health business to a consortium led by Multiples Alternate Asset Management for ₹2,921 crores. - IMPACT: The divestment may enable Zydus to concentrate more on its pharmaceutical segment, potentially affecting Mesalamine export strategies.
Impact: The divestment may enable Zydus to concentrate more on its pharmaceutical segment, potentially affecting Mesalamine export strategies.
Common Questions — Mesalamine Suppliers from India
Answers based on Indian Customs (DGFT) shipment records compiled by TransData Nexus
Q Which mesalamine supplier from India is the most reliable for bulk orders?
Based on shipment frequency and export consistency, ZYDUS LIFESCIENCES LIMITED leads with 386 recorded shipments worth $1.0B. SUN PHARMACEUTICAL INDUSTRIES LIMITED (207 shipments) and CADILA HEALTHCARE LIMITED (32 shipments) are also established high-volume exporters.
Q How many mesalamine manufacturers are there in India?
India has 103 active mesalamine exporters with a combined export market of $1.3B across 3,779 shipments to 51 countries. The top 5 suppliers hold 98.5% of total export value.
Q What certifications should I verify?
Verify: WHO-GMP certification (most markets), US FDA approval (United States), EU GMP certificate (EU/EEA), and Free Sale Certificate from CDSCO. Always request a Certificate of Analysis (CoA) and Certificate of Origin (CoO).
Q What is the typical price range for mesalamine from India?
Average FOB unit price: $13.15 per unit, ranging from $0.01 to $2657.70. Average shipment value: $349.1K.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Supplier Ranking: 103 verified Indian exporters of Mesalamine ranked by capped export value from DGFT shipping bill records.
- 2.Export Value Analysis: Total export value aggregated from 3,779 individual shipping bill records. Values are FOB in USD.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation.
- 4.Market Concentration: Supplier market share and geographic reach analyzed across 51 destination countries.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
3,779 Verified Shipments
103 exporters tracked
Expert-Reviewed
By pharmaceutical trade specialists